Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School

Last Updated: October 20, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Eculizumab

See Plans and Pricing

« Back to Dashboard

Development status for investigational drug Eculizumab: Patents, clinical trial progress, indications

Eculizumab is an investigational drug.

There have been 67 clinical trials for Eculizumab. The most recent clinical trial was a Phase 3 trial, which was initiated on November 1st 2012.

The most common disease conditions in clinical trials are Hemoglobinuria, Paroxysmal, Hemoglobinuria, and Syndrome. The leading clinical trial sponsors are Alexion Pharmaceuticals, National Heart, Lung, and Blood Institute (NHLBI), and Mario Negri Institute for Pharmacological Research.

There are seventy-one US patents protecting this investigational drug and one international patent.

Recent Clinical Trials for Eculizumab
The Use of Eculizumab in HELLP SyndromeJohns Hopkins UniversityPhase 1
Eculizumab to Cemdisiran Switch in aHUSAlnylam PharmaceuticalsPhase 2
Eculizumab to Cemdisiran Switch in aHUSMario Negri Institute for Pharmacological ResearchPhase 2

See all Eculizumab clinical trials

Clinical Trial Summary for Eculizumab

Top disease conditions for Eculizumab
Top clinical trial sponsors for Eculizumab

See all Eculizumab clinical trials

US Patents for Eculizumab

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Eculizumab   Start Trial Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein CureVac AG (Tubingen, DE)   Start Trial
Eculizumab   Start Trial Oncolytic virus adjunct therapy with agents that increase virus infectivity Genelux Corporation (San Diego, CA)   Start Trial
Eculizumab   Start Trial Treatment of paroxysmal nocturnal hemoglobinuria, hemolytic anemias and disease states involving intravascular and extravascular hemolysis Alexion Pharmaceuticals, Inc. (Boston, MA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.